Emergent Biosolutions (EBS) Tops Q2 EPS by 6c, Posts FY11 Guidance
Emergent Biosolutions (NYSE: EBS) reported Q2 EPS of $0.40, $0.06 better than the analyst estimate of $0.34. Revenue for the quarter came in at $88.1 million versus the consensus estimate of $84.2 million.
Emergent Biosolutions sees FY2011 net income of $15 to $25 million. Emergent Biosolutions sees FY2011 revenue of $270-$290 million, versus the consensus of $326.68 million.
Emergent Biosolutions sees FY2011 net income of $15 to $25 million. Emergent Biosolutions sees FY2011 revenue of $270-$290 million, versus the consensus of $326.68 million.